<?xml version="1.0" encoding="UTF-8"?>
<p id="p0125">In terms of clinical manifestations, lung cancer and COVID-19 are similar, making it difficult for clinicians to differentiate (
 <xref rid="bib54" ref-type="bibr">Yang et al., 2020a</xref>). Lung cancer patients receiving systemic immunosuppressive agents are more prone to be infected with COVID-19 as compared to healthy individuals (
 <xref rid="bib53" ref-type="bibr">Xu et al., 2020b</xref>). 
 <xref rid="bib32" ref-type="bibr">Liang et al. (2020)</xref>, surveyed 1590 COVID-19 cases, where 18 cases had a history of cancer, while five of these 18 cases had a history of lung cancer (
 <xref rid="bib51" ref-type="bibr">Xia et al., 2020</xref>). However, any conclusion to associate COVID-19 infection with cancer should be drawn carefully, as no convincing evidence is available to confirm that patients with cancer have an increased risk of being infected with COVID-19. To draw a clear conclusion, a reasonable sample size with less heterogeneity must be studied.
</p>
